{"disease":{"id":"primary-hemophagocytic-lymphohistiocytosis","name":"Primary hemophagocytic lymphohistiocytosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"emapalumab-lzsg","indication_name":"Primary hemophagocytic lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Emapalumab-Lzsg","company_name":"Swedish Orphan Biovitrum","drug_phase":"discontinued","molecular_target":"Interferon gamma","drug_class":"Interferon gamma Blocker [EPC]","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted."},{"drug_id":"emapalumab","indication_name":"Primary hemophagocytic lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gamifant","generic_name":"EMAPALUMAB","company_name":"Novimmune S.A.","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Interferon gamma Blocker [EPC]","quality_score":55,"revenue":null,"mechanism":"Gamifant works by blocking the action of interferon gamma, a protein that helps coordinate the immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03827343","title":"Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03312751","title":"Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT05744063","title":"A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT06587191","title":"Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}